Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq

MT Newswires Live

2025/12/19

Clinuvel Pharmaceuticals (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.

Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker "CLVL."

The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a "Foreign Private Issuer" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.

Its shares rose over 2% in recent trading on Friday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592135240"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592135240\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592135240?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592135240","market":"fut","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.</p><p>Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"</p><p>The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.</p><p>Its shares rose over 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-19 09:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.</p><p>Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"</p><p>The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.</p><p>Its shares rose over 2% in recent trading on Friday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"醫藥生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592135240","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592135240","pubTimestamp":1766107403,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals  filed a draft registration statement with the US Securities and Exchange Commission , seeking to uplist its American depositary receipt  program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.Its shares rose over 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7094":"医疗保健技术","ADR.AU":"Adherium Ltd","CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK4107":"财产与意外伤害保险","BK4117":"多元化保险","AFG":"美国金融集团有限公司","BK7067":"生物科技","SEC.AU":"SPHERIA EMERGING CO LTD"},"translate_title":"Clinuvel Pharmaceuticals寻求在纳斯达克上市美国存托凭证计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFG":1.5,"SEC.AU":1,"ADR.AU":1,"NQmain":1.5,"CUV.AU":1},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.Its shares rose over 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}